Sanofi (NASDAQ:SNY) Short Interest Update

Sanofi (NASDAQ:SNY) saw a large decline in short interest in April. As of April 15th, there was short interest totalling 3,240,000 shares, a decline of 16.9% from the March 31st total of 3,900,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Trading of Sanofi

Hedge funds have recently made changes to their positions in the company. Rise Advisors LLC boosted its holdings in shares of Sanofi by 98.4% during the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the period. Salem Investment Counselors Inc. acquired a new stake in Sanofi during the 4th quarter worth about $27,000. Venturi Wealth Management LLC raised its holdings in Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares during the period. Frazier Financial Advisors LLC acquired a new position in shares of Sanofi in the 4th quarter valued at about $28,000. Finally, Register Financial Advisors LLC acquired a new position in shares of Sanofi in the 1st quarter valued at about $29,000. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Morgan Stanley started coverage on shares of Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective on the stock. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, TheStreet cut shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $55.00.

Sanofi Stock Performance

Sanofi stock traded up $0.14 during trading hours on Tuesday, reaching $49.23. 3,182,534 shares of the stock were exchanged, compared to its average volume of 2,021,368. The stock has a market cap of $124.53 billion, a P/E ratio of 24.74, a P/E/G ratio of 1.48 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.93. The firm’s 50 day moving average is $47.82 and its 200 day moving average is $48.25.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The business had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. Analysts predict that Sanofi will post 4.09 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a yield of 2.98%. This is a boost from Sanofi’s previous annual dividend of $1.38. The ex-dividend date is Thursday, May 9th. Sanofi’s payout ratio is 69.35%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.